Drug Trial Radar · NCT05514509
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
295
Actual
Start
Oct 28, 2022
Primary completion
Sep 2, 2025
Study completion Sep 2, 2025
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.
Conditions
- HIV Infections
Interventions
APRETUDEDrug
Available as intramuscular injection.
Cabotegravir tabletDrug
Available as marketed orally administered tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12Time frame: At Month 12
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Bridgeport, Kansas
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.